Propanc Biopharma (PPCB) Enterprise Value (QoQ) (2016 - 2025)
Propanc Biopharma (PPCB) Enterprise Value (QoQ) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -4,886.24% |
| Jun 30, 2025 | 76.19% |
| Mar 31, 2025 | -246.89% |
| Dec 31, 2024 | -57.89% |
| Sep 30, 2024 | 56.04% |
| Jun 30, 2024 | -238.88% |
| Mar 31, 2024 | 91.32% |
| Dec 31, 2023 | -981.51% |
| Sep 30, 2023 | 34.06% |
| Jun 30, 2023 | 89.22% |
| Mar 31, 2023 | -280.95% |
| Dec 31, 2022 | -26.19% |
| Sep 30, 2022 | -376.91% |
| Dec 31, 2021 | -60.67% |
| Sep 30, 2021 | -1,931.80% |
| Jun 30, 2021 | 84.38% |
| Mar 31, 2021 | 32.03% |
| Mar 31, 2020 | -124.23% |
| Dec 31, 2019 | 87.49% |
| Sep 30, 2019 | -3,915.16% |